Live Breaking News & Updates on Krys Elfried Digbehi|Page 6
Stay updated with breaking news from Krys elfried digbehi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Krystal Biotech (NASDAQ:KRYS – Get Rating) and Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability. Profitability This table compares Krystal Biotech and Neurocrine Biosciences’ […] ....
Advisory Research Inc. lessened its stake in Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) by 4.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 10,354 shares of the company’s stock after selling 465 shares during the quarter. Advisory Research Inc.’s holdings […] ....
Krystal Biotech (NASDAQ:KRYS – Get Rating) had its price objective upped by Stifel Nicolaus from $102.00 to $145.00 in a report issued on Wednesday, The Fly reports. A number of other analysts also recently weighed in on the stock. Bank of America boosted their target price on shares of Krystal Biotech from $105.00 to $118.00 […] ....
Krystal Biotech (NASDAQ:KRYS – Get Rating) had its price objective lifted by Stifel Nicolaus from $102.00 to $145.00 in a research report released on Wednesday morning, The Fly reports. Several other research analysts have also recently commented on KRYS. William Blair restated an outperform rating on shares of Krystal Biotech in a research report on […] ....
Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) – Equities research analysts at HC Wainwright raised their Q3 2023 earnings per share (EPS) estimates for Krystal Biotech in a research note issued to investors on Monday, May 22nd. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($1.02) per share for […] ....